Skip to content

Research at St Andrews

PRIMA-1Met suppresses colorectal cancer independent of p53 by targeting MEK

Research output: Contribution to journalArticle


Tao Lu, Yanmei Zou, Guogang Xu, Jane A. Potter, Garry L. Taylor, Qiuhong Duan, Qin Yang, Huihua Xiong, Hong Qiu, Dawei Ye, Peng Zhang, Shiying Yu, Xianglin Yuan, Feng Zhu, Yihua Wang, Hua Xiong

School/Research organisations


PRIMA-1Met is the methylated PRIMA-1 (p53 reactivation and induction of massive apoptosis) and could restore tumor suppressor function of mutant p53 and induce p53 dependent apoptosis in cancer cells harboring mutant p53. However, p53 independent activity of PRIMA-1Met remains elusive. Here we reported that PRIMA-1Met attenuated colorectal cancer cell growth irrespective of p53 status. Kinase profiling revealed that mitogen-activated or extracellular signal-related protein kinase (MEK) might be a potential target of PRIMA-1Met. Pull-down binding and ATP competitive assay showed that PRIMA-1Met directly bound MEK in vitro and in cells. Furthermore, the direct binding sites of PRIMA-1Met were explored by using a computational docking model. Treatment of colorectal cancer cells with PRIMA-1Met inhibited p53-independent phosphorylation of MEK, which in turn impaired anchorage-independent cell growth in vitro. Moreover, PRIMA-1Met suppressed colorectal cancer growth in xenograft mouse model by inhibiting MEK1 activity.

Taken together, our findings demonstrate a novel p53-independent activity of PRIMA-1Met to inhibit MEK and suppress colorectal cancer growth.



Original languageEnglish
Pages (from-to)83017-83030
Number of pages14
Issue number50
StatePublished - 27 Oct 2016

    Research areas

  • Colorectal cancer, MEK, p53, PRIMA-1Met, Tumorigenesis

Discover related content
Find related publications, people, projects and more using interactive charts.

View graph of relations

Related by author

  1. Streptococcus pneumoniae NanC. Structural insights into the specificity and mechanism of a sialidase that produces a sialidase inhibitor

    Owen, C. D., Lukacik, P., Potter, J. A., Sleator, O., Taylor, G. L. & Walsh, M. A. 13 Nov 2015 In : Journal of Biological Chemistry. 290, 46, p. 27736-27748 13 p.

    Research output: Contribution to journalArticle

  2. Towards a Hepatitis C Vaccine: the Structural Basis of Hepatitis C Virus Neutralization by AP33, a Broadly Neutralizing Antibody

    Potter, J. A., Owsianka, A., Jeffrey, N., Matthews, D., Keck, Z-Y., Lau, P., Taylor, G. L. & Patel, A. 2012 In : Journal of Virology. 86, 23, p. 12923-12932

    Research output: Contribution to journalArticle

  3. The structure of Sulfolobus solfataricus 2-keto-3-deoxygluconate kinase

    Potter, J. A., Kerou, M., Lamble, H. J., Bull, S. D., Hough, D. W., Danson, M. J. & Taylor, G. L. Dec 2008 In : Acta Crystallographica. Section D, Biological crystallography. 64, p. 1283-1287 5 p.

    Research output: Contribution to journalArticle

Related by journal

  1. A signaling visualization toolkit to support rational design of combination therapies and biomarker discovery: SiViT

    Brown, J. L., Shovman, M., Robertson, P., Boiko, A., Goltsov, A., Mullen, P. & Harrison, D. J. May 2017 In : Oncotarget. 8, 18, p. 29657-29667 11 p.

    Research output: Contribution to journalArticle

  2. Inhibition of pH regulation as a therapeutic strategy in hypoxic human breast cancer cells

    Meehan, J., Ward, C., Turnbull, A., Bukowski-Wills, J., Finch, A., Jarman, E. J., Xintaropoulou, C., Martinez-Perez, C., Gray, M., Pearson, M., Mullen, P., Supuran, C. T., Carta, F., Harrison, D. J., Kunkler, I. H. & Langdon, S. 2017 In : Oncotarget. 8, 26, p. 42857-42875

    Research output: Contribution to journalArticle

  3. A novel mechanism of action of HER2 targeted immunotherapy is explained by inhibition of NRF2 function in ovarian cancer cells

    Khalil, H. S., Langdon, S. P., Goltsov, A., Soininen, T., Harrison, D. J., Brown, J. & Deeni, Y. Y. 2016 In : Oncotarget. 7, 46, p. 75874-75901

    Research output: Contribution to journalArticle

  4. Delta-9-tetrahydrocannabinol protects against MPP+ toxicity in SH-SY5Y cells by restoring proteins involved in mitochondrial biogenesis

    Zeissler, M-L., Eastwood, J., McCorry, K., Hanemann, C. O., Zajicek, J. P. & Carroll, C. B. 27 Jun 2016 In : Oncotarget. 7, 29, p. 46603-46614 12 p.

    Research output: Contribution to journalArticle

  5. Dynamic epigenetic changes to VHL occur with sunitinib in metastatic clear cell renal cancer

    Stewart, G. D., Powles, T., Van Neste, C., Meynert, A., O'Mahony, F., Laird, A., Deforce, D., Van Nieuwerburgh, F., Trooskens, G., Van Criekinge, W., De Meyer, T. & Harrison, D. J. 23 Mar 2016 In : Oncotarget. 7, 18, 10 p.

    Research output: Contribution to journalArticle

ID: 248518350